Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%
Market cap
$13.8B
P/E
34.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

15.00 25.79 22.13 22.24
P/S ratio
6.92 5.77 5.06 5.52
P/FCF ratio
11.62 12.51 11.44 11.39
P/Operating CF
48.14 36.82 42.40 38.10
P/B ratio
17.06 165.22 34.77 63.95
EV/Sales
7.57 7.72 6.27 6.67
EV/EBITDA
11.46 19.20 15.27 15.43
EV/FCF
12.72 16.72 14.17 13.76
Current Ratio
1.59 4.66 2.76 2.71
Net Debt/EBITDA
3.37 (31.07) 8.28 5.93
Debt/Equity
3.00 43.89 9.76 14.95
Earnings Yield
6.67% 3.88% 4.52% 4.50%
Free Cash Flow Yield
8.60% 7.99% 8.74% 8.78%
Free Cash Flow per Share
5.33 (1.93) 1.49 2.02
Book value per Share
4.30 0.41 1.86 1.22
Free Cash Flow
624.44 (231.27) 176.34 236.72
EV/EBIT
12.76 22.98 18.48 18.58
Other line items

Show all line items

Columns are period end dates